Cambridge Healthtech Institute’s 20th Annual

Engineering Antibodies
( 抗体工程 )

New Science and Technologies for the Selection, Engineering and Targeting of Next Generation Therapeutic Antibodies and Biotherapeutics

2019年4月10~11日

 

The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now progressing through development and into the market, great advances in protein science and discovery technology and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. The PEGS Engineering Antibodies conference explores case examples of the most significant emerging technologies used by protein engineers working at the discovery and design stages to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions.

Preliminary Agenda

DEEP SEQUENCING AND B-CELL CLONING IN ANTIBODY DISCOVERY

Antibody Affinity and Repertoires from Single Antibody-Producing Cells

Pierre Bruhns, PhD, Professor, Antibodies in Therapy & Pathology, Pasteur Institute, France

Microfluidics Technology to Identify and Isolate Antigen-Specific Interferon γ-Secreting T Cells

Julie Brouchon, PhD, Postdoctoral Researcher, Weitz Lab, Harvard University

High Throughput Antibody Discovery in the Digital Age

Jane Seagal, PhD, Principal Research Scientist, Global Biologics, AbbVie

ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN ANTIBODY DISCOVERY

Machine Learning for Antibody Discovery

Sai Reddy, PhD, Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

KEYNOTE PRESENTATION: Implementing Artificial Intelligence in Biotherapeutic Discovery and Development

Philip Tagari, PhD, Vice President, Research, Amgen

Machine Learning in Computational Biology to Accelerate Heterologous Protein Production

Elizabeth Brunk, PhD, Postdoctoral Research Fellow, Systems Biology Research Group, University of California, San Diego

Luncheon Presentation: Build Better Biologics with Machine Learning and Synbio

Claes Gustafsson, PhD, CCO, Co-Founder, ATUM

FAST AND NIMBLE ANTIBODY DISCOVERY AND DEVELOPMENT

Lessons Learned on Rapid Discovery from the DARPA Pandemic Prevention Platform (P3)

Gregory C. Ippolito, PhD, Research Assistant Professor, Molecular Biosciences, LIVESTRONG Cancer Institute, The University of Texas at Austin

Case Study of Antibody Discovery and Development from a Small and Nimble Biotech

Abhishek Datta, PhD, Director, Antibody Discovery & Engineering, Scholar Rock

Presentation to be Announced

EMERGING TECHNOLOGIES IN ANTIBODY ENGINEERING

A Paradigm Shift: Moving from Traditional Screening Towards Data Driven Antibody Design

Kristin Brown, Director, Protein Design and Informatics, GlaxoSmithKline

New High-Throughput Technologies to Design and Optimize Non-Antibody Scaffolds

Gabriel Rocklin, PhD, Senior Fellow, Molecular Engineering and Sciences, University of Washington

Presentation to be Announced

OPTIMIZING ANTIBODY TARGETING AND SPECIFICITY

Using Deep Sequencing Datasets to Tailor Specificity

Tim Whitehead, PhD, Associate Professor, Chemical and Biological Engineering, University of Colorado, Boulder

Engineering of a T-cell Dependent Bispecific Antibody to Broaden the Therapeutic Index for Solid Tumors

Christoph Spiess, PhD, Senior Scientist, Antibody Engineering, Genentech

Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries

K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

SelexisPresentation to be Announced

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English




Premier Sponsors


显示切换



免费电子邮件通知服务